Rapamycin / sirolimus (off-label, low-dose intermittent)

The lifespan case rests on animal data, not humans. Rodent evidence is genuinely robust and reproducible, which is why rapamycin is taken seriously by ageing biologists rather than dismissed. Human evidence is far thinner. A 2025 review in Aging identified fewer than a dozen trials of low-dose rapamycin or analogues in healthy participants, and concluded that human data "has yet to establish that rapamycin, or its analogues, is an effective seno-therapeutic to delay aging in healthy older adults." The human trials that exist are small, short, and measure surrogate endpoints rather than ageing outcomes: Kraig 2018 dosed 25 adults aged 70 to 95 with 1 mg/day for 8 weeks; Mannick's work used the analogue everolimus and RTB101 for immune and respiratory-infection endpoints, and the phase 3 results failed to replicate the earlier phase 2b signal. Kaeberlein's 333-user cohort is observational and unblinded, so it cannot support causal claims. No human trial has demonstrated extended healthspan or lifespan. Documented adverse findings in these studies include raised triglycerides and HbA1c, reduced plasma albumin and haemoglobin, elevated TNF-alpha, oral ulcers, and increased anxiety at some doses, so this is not a low-consequence intervention and it carries genuine immunosuppression risk requiring baseline and ongoing bloodwork. Grading this as preclinical rather than clinical is deliberate: human RCTs exist, but none establish the healthspan outcome the protocol is sold on.

What it is

Plain-language explainer

Categories

Common questions

What is Rapamycin / sirolimus (off-label, low-dose intermittent)?

The lifespan case rests on animal data, not humans. Rodent evidence is genuinely robust and reproducible, which is why rapamycin is taken seriously by ageing biologists rather than dismissed. Human evidence is far thinner. A 2025 review in Aging identified fewer than a dozen trials of low-dose rapamycin or analogues in healthy participants, and concluded that human data "has yet to establish that rapamycin, or its analogues, is an effective seno-therapeutic to delay aging in healthy older adults." The human trials that exist are small, short, and measure surrogate endpoints rather than ageing outcomes: Kraig 2018 dosed 25 adults aged 70 to 95 with 1 mg/day for 8 weeks; Mannick's work used the analogue everolimus and RTB101 for immune and respiratory-infection endpoints, and the phase 3 results failed to replicate the earlier phase 2b signal. Kaeberlein's 333-user cohort is observational and unblinded, so it cannot support causal claims. No human trial has demonstrated extended healthspan or lifespan. Documented adverse findings in these studies include raised triglycerides and HbA1c, reduced plasma albumin and haemoglobin, elevated TNF-alpha, oral ulcers, and increased anxiety at some doses, so this is not a low-consequence intervention and it carries genuine immunosuppression risk requiring baseline and ongoing bloodwork. Grading this as preclinical rather than clinical is deliberate: human RCTs exist, but none establish the healthspan outcome the protocol is sold on.

How strong is the evidence for Rapamycin / sirolimus (off-label, low-dose intermittent)?

Preclinical. Evidence comes from laboratory or animal work, not from human trials.

Is Rapamycin / sirolimus (off-label, low-dose intermittent) approved in Singapore?

Health Sciences Authority position on record: Registered with HSA as a prescription-only therapeutic product (RAPAMUNE tablets, 0.5 mg and 1 mg). The Singapore National Drug Formulary lists sirolimus for kidney transplant immunosuppression in patients with CNI-induced nephrotoxicity, elevated serum creatinine, or CNI hypersensitivity, subsidised via the Medical Assistance Fund in public healthcare institutions. There is no HSA-approved longevity or healthspan indication, so any such use would be off-label. No Singapore clinic was found publicly offering it for longevity.. An evidence grade and a regulatory approval are different questions.

Is Rapamycin / sirolimus (off-label, low-dose intermittent) approved in Australia?

Therapeutic Goods Administration position on record: Registered on the ARTG as RAPAMUNE (sirolimus) and classified Schedule 4 Prescription Only Medicine. The approved indication is prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants, with therapeutic drug monitoring required. There is no TGA-approved longevity or anti-ageing indication; longevity use is off-label prescribing by an individual doctor, which is legal in Australia but not TGA-endorsed.. An evidence grade and a regulatory approval are different questions.

What else is Rapamycin / sirolimus (off-label, low-dose intermittent) called?

Also known as Sirolimus, Rapamune, mTOR inhibitor, Low-dose intermittent rapamycin.